Erwin Villavert
Family · Duarte, CANPI 1598987331
Payments from drug & device makers
Across 31 payments — averaging $24.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$166
- Johnson & Johnson$77
- Eisai Inc.$70
- Teleflex LLC$69
- Ferring Pharmaceuticals Inc.$40
- Sun Pharmaceutical Industries Inc.$39
- plus $297 from 10 others
What the payments were for
- Food & beverage$757100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 7 | $166 |
| Johnson & Johnson | 3 | $77 |
| Eisai Inc. | 3 | $70 |
| Teleflex LLC | 3 | $69 |
| Ferring Pharmaceuticals Inc. | 2 | $40 |
| Sun Pharmaceutical Industries Inc. | 1 | $39 |
| Genentech USA, Inc. | 1 | $35 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $33 |
| Dendreon Pharmaceuticals LLC | 1 | $33 |
| Seagen Inc. | 2 | $33 |
| Urovant Sciences Inc | 1 | $31 |
| Amgen | 2 | $31 |
| Tempus AI, Inc | 1 | $29 |
| Incyte Corporation | 1 | $26 |
| Pfizer | 1 | $23 |
| Bayer | 1 | $21 |
How this compares
$757 in reported general payments places this provider in the 70th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 55 | $27,560 |
| Silodosin | 41 | $4,574 |
| Mirabegron ErMirabegron | 19 | $4,483 |
| Tamsulosin Hcl | 176 | $3,229 |
| Oxybutynin Chloride ErOxybutynin Chloride | 21 | $928 |
| Solifenacin Succinate | 22 | $766 |
| Finasteride | 42 | $613 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 30 | $439 |
| Tadalafil | 11 | $246 |
| Cefdinir | 14 | $107 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $69 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 23 | $24 |
Paid to pharmacies, not to this prescriber.
Other family in Duarte
- Maria Elena Dela RosaDuarte$55K
- Marjorie HeinDuarte$50K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.